Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.
Last trade$8.13
Day change+$0.155 (+1.94%)
Day range$7.70 – $8.20
Volume289,259
Market cap$409M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$409.26M
Price / earnings
—
Price / book
1.52×
Price / sales
7.76×
EV / sales
2.61×
EV / EBITDA
-3.66×
Profitability
Earnings per share
-$0.47
Return on assets
-8.45%
Return on equity
-8.91%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
23.95×
Quick ratio
23.95×
Cash ratio
23.73×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$32.17M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for PRTA, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$620K
$1.01M
$51.08M
$21K
$2.42M
$4.42M
$2.83M
$2.12M
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$620K
$1.01M
$51.08M
$21K
$2.42M
$4.42M
$2.83M
$2.12M
Selling, general and administrative
$10.59M
$10.9M
$12.67M
$12.65M
$13.24M
$15.91M
$17.6M
$16.85M
Research and development
$8.43M
$8.8M
$12.63M
$14.59M
$28.94M
$40.52M
$50.81M
$50.17M
Total operating expenses
$19.44M
$22.11M
$21.05M
$24.22M
$42.66M
$89.04M
$68.41M
$67.02M
Operating income
-$18.82M
-$21.1M
$30.04M
-$24.2M
-$40.24M
-$84.62M
-$65.58M
-$64.9M
Interest expense
$0
$0
$0
$2.65M
$0
$0
$0
$5.39M
Income before taxes
-$16.51M
-$18.58M
$32.72M
-$21.58M
-$36.91M
-$80.97M
-$61.37M
-$59.5M
Income taxes
$2K
$2K
$1K
$10K
-$371K
$44.8M
-$1.18M
-$1.55M
Net income
-$16.51M
-$18.58M
$32.72M
-$21.59M
-$36.54M
-$125.77M
-$60.2M
-$57.96M
Net income attributable to common shareholders
-$16.51M
-$18.58M
$32.72M
-$21.59M
-$36.54M
-$125.77M
-$60.2M
-$57.96M
EBITDA
-$18.19M
-$18.49M
$25.98M
-$26.99M
-$39.53M
-$51.78M
-$65.36M
-$64.68M
Basic earnings per share
-$0.32
-$0.36
$0.61
-$0.40
-$0.68
-$2.34
-$1.12
-$1.08
Diluted earnings per share
-$0.32
-$0.36
$0.60
-$0.40
-$0.68
-$2.34
-$1.12
-$1.10
Recent news
Company coverage with links to the original publishers.
Prothena (PRTA) has a mean analyst price target of $19.33, suggesting 120.2% upside potential from its current $8.78 price. The stock holds a Zacks Rank #2 (Buy) rating, supported by strong earnings estimate revisions that increased 58.8% over the past month. However, the article cautions that price targets alone should not drive investment decisions, as analysts often set overly optimistic targets due to business incentives.
Prothena (PRTA) reported a quarterly loss of $0.32 per share, beating consensus estimates of $0.38 loss, representing a 15.79% earnings surprise. However, the company missed revenue expectations significantly, posting $0.62 million versus the consensus estimate, down from $2.41 million year-over-year. The stock has underperformed the market by 24.5% year-to-date and carries a Zacks Rank #3 (Hold) rating.
Prothena Corporation relies on partnerships with major pharmaceutical companies (Roche, Novo Nordisk, and Bristol Myers Squibb) to advance its neurodegenerative and rare disease treatments. The company received a $50M milestone payment for coramitug and estimates $3B in total future milestone payments plus royalties from partnered programs. While partnerships reduce financial burden and provide expertise, they also limit Prothena's control over key programs and expose the company to clinical and commercial risks.
In a comparison of two medical-biomedical stocks, CorMedix (CRMD) emerges as the superior value option over Prothena (PRTA). CRMD holds a Zacks Rank of #2 (Buy) with a Value grade of A, featuring a forward P/E of 13.48 and PEG ratio of 1.35. PRTA, ranked #3 (Hold) with a Value grade of F, has a forward P/E of 66.51 and PEG ratio of 1.99, indicating it is significantly more expensive relative to its growth prospects.
The transthyretin amyloidosis treatment market is projected to grow from USD 8.95 billion in 2025 to USD 35.10 billion by 2035 at a 14.64% CAGR. Growth is driven by increased ATTR-CM diagnosis rates, FDA approvals of gene-silencing therapies like vutrisiran and acoramidis, improved diagnostic imaging, and expanding pipeline therapies. North America dominates with 46% market share, while Asia Pacific is the fastest-growing region.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.